Stoke Therapeutics, Inc. (STOK) stock
STOKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30173% above fair value
$26.41−0.22 (-0.83%)
Close on Nov 17, 2026Market cap $1.70BP/E –Yield –
Stoke Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Stoke Therapeutics's price to sales ratio was 62.8× on Nov 11, 2026, against 8.3× a year earlier. Over the last 4 years it ranged from 2.7× to 88.7×, with a median of 28.3×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 62.8× | +54.3 |
| 2025 | Dec 31, 2025 | 8.5× | −26.4 |
| 2024 | Dec 31, 2024 | 34.9× | +9.7 |
| 2023 | Dec 29, 2023 | 25.2× | – |
See a number that looks wrong?